PolyModels Hub has secured £7 million in Series A financing to scale its digital platform for biopharma process development and manufacturing. The round, announced in London on 20 November 2025, was led by Molten Ventures with participation from Marathon Venture Capital. The company aims to use the fresh capital to strengthen its technology, grow its team, and deepen its global footprint across pharmaceutical and biotech organizations.
Series A fuels biopharma’s digital backbone
The funding will be directed toward expanding PolyModels Hub’s engineering and product capabilities, as well as enhancing its core software platform. The company plans to build out scalable solutions that address process and regulatory workflows, enabling pharma teams to adopt digital tools without disrupting existing operations. By focusing on infrastructure rather than point solutions, PolyModels Hub positions itself as a long-term backbone for modern biopharma development.
Transforming process development economics
Drug development remains a capital-intensive endeavor, with industry estimates putting the cost of bringing a new therapy to market at roughly $2.5 billion. Around a quarter of that total, approximately $650 million, is typically absorbed by process development activities that underpin manufacturing at scale. PolyModels Hub argues that digitizing and optimizing these workflows represents one of the most powerful levers to reduce cost, increase speed, and improve reproducibility across the pipeline.
ModelFlow integrates modeling, simulation, and workflows
At the center of the company’s proposition is ModelFlow, an integrated digital environment that combines modeling, simulation, and workflow management. The platform allows scientists and engineers to design, test, and refine manufacturing processes more rapidly by unifying data and expertise across teams, sites, and functions. By blending physics-based models with AI-driven approaches inside structured, traceable workflows, ModelFlow is designed to cut experimental burden while improving process understanding and decision quality.
From experiment-heavy processes to data-driven clarity
In traditional settings, process optimization often relies on dozens or even hundreds of physical experiments that can take weeks or months to complete. Early deployments of ModelFlow have reportedly reduced experimental workloads by more than 90 percent, shrinking 100-experiment campaigns to fewer than ten while maintaining or enhancing scientific robustness. This shift reflects a broader industry move toward treating process development as a strategic driver of speed, quality, and regulatory success, particularly as modalities diversify from small molecules to complex biologics and emerging platforms.
Deepening focus on complex biologics and automation
PolyModels Hub is doubling down on complex biologics and AI-led automation as it pursues its longer-term vision. That vision centers on building a unified digital layer that supports the journey from early discovery through to commercial manufacturing with consistency, scientific rigor, and high levels of automation. The team brings together scientists and engineers from life sciences and technology backgrounds who have previously built systems in highly regulated and technically demanding environments.
Investor confidence and strategic backing
CEO and co-founder Antonio Benedetti described the sector as undergoing a “once-in-a-generation digital transformation,” highlighting how PolyModels Hub has delivered tangible value across multiple programs in just 18 months. Molten Ventures CEO Ben Wilkinson said the startup is addressing a real pain point for pharma teams, praising the combination of deep domain expertise and advanced technology and noting the platform’s ability to deliver value “in weeks, not years.” Marathon Venture Capital partner Alex Alexakis emphasized that much of pharma still relies on archaic lab processes and framed PolyModels Hub as a key player in redesigning how the industry uses data and automation to develop medicines.
Operating at the intersection of science, engineering, and data, PolyModels Hub is positioning ModelFlow as the digital backbone for next-generation biopharma process development. By connecting models, experiments, and decisions within a single environment, the company aims to help development teams move from complexity to clarity while accelerating access to high-quality therapies. With its new Series A funding and backing from Molten Ventures and Marathon Venture Capital, PolyModels Hub is set to scale its impact across global pharma and biotech, bringing better medicines to patients faster.